Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Almost new. 3 days old but I haven't seen it mentioned here.
Tom starts talking at 02:15. Lasts about 10 mins.
https://www.**********.co.uk/articles/feedback-plc-chris-bailey-on-3-big-caps-john-meyer-on-3-small-resource-stocks-f9fb958/
https://bleepa.com/clinical-information-data-quality-and-auditing
They aren't taking on 'more free customers' and the majority of the £5.27 mil spent to date was on a Bleepa upgrade - a non-recurring cost one would hope - also they've already banked £120k in the first 8 days of the current financial year (see today's RNS).
'The Company has already invoiced £0.12million of revenue to be recognised during the current financial year in accordance with the Company's accounting policies and the Directors expect revenues to grow as sales of Bleepa increase during the rest of the financial year.'
They need to bank around £200k a month to break even at present.
If they continue to bank £120k every 8 days then they would bank £5.475 mil a year.
To break even this financial year they need to bank £120k every 20 days.
Only if they sell nothing more in the next 6-8 months will they need to come back to the market for more funds in this timeframe. If that happens you will have more to worry about than another placing.
https://www.nhsconfedconference.org/conference-agenda
Taking stock of messaging apps: using safe, secure and compliant clinical messaging to drive efficiencies, negate clinical risk and improve care delivery
17 Jun 2021 08:00 - 08:55 S - Specialist sessions 3
The European Commission’s Medical Device Directive states that any platform that ‘displays digital patient images for the purpose of diagnosis’ by clinicians should hold a CE mark as a regulated medical device. However, with the current prevalence of clinicians using mainstream messaging and clinical communication platforms without it, there is a considerable liability risk for both organisations and individual clinicians.
Healthcare organisations also have an obligation under GDPR as data controllers, which means that communication apps that contain patient information should include a data processing agreement between the manufacturer and any organisation whose employees are using it. This applies to apps offered to clinicians under a ‘freemium’ model, even if the organisation itself has not encouraged the use of the tool and, in many cases, its clinicians may be using it outside of the organisation's knowledge.
This panel discussion seeks to explore the broader benefits of using a safe, secure and compliant clinical communications platform, including integrating with other clinical systems; recording discussions as part of the patient record; and improving efficiencies and working practices for busy clinicians at a time when the elective care backlog is particularly challenging.
This session is delivered in partnership with Feedback Medical Ltd
Speakers
Darryn Hale, Senior Associate - DAC Beachcroft
Dr Tom Oakley, CEO - Feedback Medical Ltd
What you say is true about new management but I'm reasonably certain that TB retains a host of negative feelings towards all things Feedback and wants nothing but harm to befall it. Beneficial or not I can't see him coming back to Feedback for a joint venture. I'd go as far as saying TB would want total control and nothing less than that would entice him back. IQAI's ownership of StoneChecker and the version of Texrad within provide no income to Feedback so far and as such no business relationship exists.
I've never considered whether it would make sense or not because I just can't see it happening.
The CEO of IQAI was on the board of Feedback some years ago. He didn't leave on good terms so I heard. I would be amazed if he chose to ever have anything to do with Feedback, or Feedback with him. From time to time he still posts on the Feedback chat boards and his posts are normally negative in nature.
Hi Bob, I haven't heard from you in awhile. The burn rate is a concern I agree which is why we need some more contracts to be announced. It was always going to be a problem getting contracts in the last financial year because of Covid-19 and all hospital trusts having end-March year ends (no available funds in a pandemic). Things should become easier now and I'm looking forward to contacts news soon. Yes, TexRAD still produces revenue just not enough for the size of the company now. India, for its size alone should be a game changer but they are in an even worse position than the UK was a year ago. I doubt we will see many contracts from there in the current climate.
I'm keeping well thanks other than the loss of some sight in one of my eyes. The worst I've been was immediately after my first Astra Zeneca jab. I won't go into all the details here but I was pretty rough for a few weeks. Bad enough that I decided to ditch the follow up jab three months later. I'll probably get another come autumn / winter but not AZ if I can help it.
Hope you are keeping well. It's been nice to hear from you again.
Regards, Elartu.
Digital can help unclog your elective care back-log
New digital solutions that support asynchronous communication between clinicians could transform elective care and aid in tackling the expanding waiting lists
https://www.hsj.co.uk/technology-and-innovation/digital-can-help-unclog-your-elective-care-back-log/7030013.article
COVID-19 having 'catastrophic' impact on NHS as 4.7 million wait to start hospital treatment
https://news.sky.com/story/boris-johnson-has-no-doubt-record-4-7m-nhs-treatment-list-backlog-can-be-tackled-12276297
4.7 million waiting to begin treatment - that's approximately 7% of the UK population. 1 person in 14.